

## Original Article

## Effect of umbilical cord blood stem cells transplantation on bladder dysfunction induced by cerebral ischemia in rats

Ching-Chung Liang<sup>a, b, \*</sup>, Tsong-Hai Lee<sup>b, c</sup>, Shuenn-Dhy Chang<sup>a, b</sup><sup>a</sup> Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital Linkou Medical Center, Taoyuan, Taiwan<sup>b</sup> Department of Obstetrics and Gynecology, College of Medicine, Chang Gung University, Taoyuan, Taiwan<sup>c</sup> Stroke Section, Department of Neurology and Stroke Center, Chang Gung Memorial Hospital Linkou Medical Center, Taoyuan, Taiwan

## ARTICLE INFO

## Article history:

Accepted 2 November 2015

## Keywords:

bladder  
cord blood stem cell  
cystometry  
middle cerebral artery occlusion  
stroke

## ABSTRACT

**Objective:** To demonstrate the effect of human umbilical cord blood-derived CD34<sup>+</sup> cells on bladder dysfunction induced by cerebral ischemia in rats.**Materials and Methods:** Female rats were subjected to either 60 minute middle cerebral artery occlusion (MCAO) or a sham operation. Rats were divided into four groups: sham operation, MCAO without treatment, infusion with  $1 \times 10^6$  CD34<sup>+</sup> cells 30 minutes before MCAO, and infusion with  $1 \times 10^6$  CD34<sup>+</sup> cells 3 hours after MCAO. Bladder function was analyzed by cystometry at 1 day, 3 days, and 7 days after MCAO. Expressions of nerve growth factor (NGF), M<sub>2</sub> and M<sub>3</sub> muscarinic receptors were measured by immunohistochemistry and real time polymerase chain reaction.**Results:** Cystometric results showed that, following MCAO, rats have a significant increase in peak voiding pressure and residual volume. Conversely, there is a significant decrease in voided volumes and intercontraction intervals. Cystometric variables after pre- and postischemic CD34<sup>+</sup> treatment nearly returned to levels found in sham-operated rats. The expression of bladder NGF and M<sub>3</sub> was decreased after MCAO, but significantly increased following preischemic CD34<sup>+</sup> treatment. There was decreased expression of bladder M<sub>2</sub> mRNA despite an increased level of M<sub>2</sub> immunoreactivity at 3 days and 7 days after MCAO. Expression of bladder M<sub>2</sub> immunoreactivity and mRNA nearly returned to sham group levels after preischemic CD34<sup>+</sup> treatment.**Conclusion:** Bladder dysfunction in a rat model caused by MCAO may be restored to normal micturition by treatment with human umbilical cord blood-derived CD34<sup>+</sup> cells and may be related to the expressions of NGF, M<sub>2</sub>, and M<sub>3</sub> in the bladder.Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

Cerebral stroke has ranked as one of the leading causes of death worldwide. Poststroke mortality and chronic neurological disability are the result of neuronal damage for which there is currently no effective preventive treatment. Recent data suggest that human umbilical cord blood (HUCB)-derived CD34<sup>+</sup> cells may promote functional recovery in an animal model of stroke [1]. Several mechanisms of HUCB recovery action were suggested including

reduction of damaged cells, recognition of nerve fibers by trophic actions, reduction in inflammatory response, and enhancement of angiogenesis [1]. However, no study has been conducted to demonstrate that HUCB-derived CD34<sup>+</sup> cells can mediate therapeutic effects on bladder dysfunction following cerebral stroke, although voiding dysfunction is common in patients with cerebrovascular diseases.

Bladder overactivity induced by middle cerebral artery occlusion (MCAO) in rats has been found to involve receptors in the brain such as dopamine, glutamate, and gamma-aminobutyric acid [2–6]. Nerve growth factor (NGF) and muscarinic receptors in cerebral-infarcted rats also play a role in regulation of the micturition reflex in central and peripheral nervous systems [4,7,8]. There is a significant reduction of brain NGF after severe cerebral ischemia

\* Corresponding author. Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Linkou Medical Center, 5, Fu-Shin Street, Kweishan, Taoyuan 333, Taiwan.

E-mail address: [ccjoliang@cgmh.org.tw](mailto:ccjoliang@cgmh.org.tw) (C.-C. Liang).

[7]. NGF has an effect on bladder dysfunction by mediating morphological and functional changes in sensory neurons innervating the bladder [8]. Muscarinic receptors in the brain contribute to control of the micturition reflex [4]. A significant increase in the density of muscarinic receptors has been found in the urinary bladder of cerebral-infarcted rats [9]. The present study was conducted to evaluate whether: (1) the protective effect of HUCB-derived CD34<sup>+</sup> cells against cerebral vascular disease may improve bladder dysfunction; and (2) HUCB-derived CD34<sup>+</sup> cells treatment may sustain the expression of NGF and muscarinic receptors in the bladder.

## Materials and methods

### Animal model


All protocols were approved by the Institutional Ethics Committee for the Care and Use of Experimental Animals and the Institutional Review Board of Chang Gung Memorial Hospital Linkou Medical Center, Taoyuan, Taiwan. Female Sprague Dawley rats from the National Laboratory Animal Center (Taipei, Taiwan) were maintained at 21–23°C room temperatures and 47% humidity with a 12-hour light-dark cycle with free access to standard laboratory chow and tap water. Because endogenous estrogen may improve stroke outcome during MCAO [10], all rats in this study underwent bilateral ovariectomy performed 2 weeks before MCAO to create a hypoestrogenic menopausal state. Rats were subjected to either 60 minute MCAO or sham operation. All animal

experiments were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publications Number 80–23) revised 1996.


Clinically available tools such as recombinant tissue plasminogen activator were found to have a therapeutic window of 3–5 hours for the treatment of stroke [11]. In order to study the effect of HUCB-derived CD34<sup>+</sup> cells on the bladder dysfunction before and after ischemic insult, 72 rats (270–320 g) were randomly assigned to four groups: (1) sham operation; (2) rats with MCAO but no CD34<sup>+</sup> cells treatment; (3) rats infused with  $1 \times 10^6$  CD34<sup>+</sup> cells 30 minutes before MCAO (preischemic treatment group); and (4) rats infused with  $1 \times 10^6$  CD34<sup>+</sup> cells 3 hours after MCAO (postischemic treatment group). Bladder function was analyzed using conscious cystometry at 1 day, 3 days, and 7 days after MCAO (6 rats in each time point). Expressions of NGF, M<sub>2</sub> muscarinic receptor (M<sub>2</sub>), and M<sub>3</sub> muscarinic receptor (M<sub>3</sub>) were measured by immunohistochemistry and real time polymerase chain reaction (PCR).

### Induction of cerebral ischemia

Left MCAO was used as an acute ischemic model according to previously reported methods [12]. Rats were anesthetized with 2% isoflurane in oxygen. Following satisfactory anesthesia, the proximal portion of the external carotid artery was tightly ligated with a silk suture. A 20 mm 4-0 nylon surgical thread was inserted from the left external carotid artery into the internal carotid artery to occlude the MCA. The left common carotid artery was then permanently ligated and the wound was temporarily closed.



**Figure 1.** Cystometric results in the experimental rats (A–D) are presented (6 rats in each group). Ischemic rats show a significant increase in peak voiding pressure (A) and residual volume (D) but significant decrease in voided volume (B) and intercontraction interval (C) from 1 day to 7 days after middle cerebral artery occlusion (MCAO). \*Compared with sham-operated group,  $p < 0.05$ . Pretreatment: preischemic treatment, posttreatment: postischemic treatment.



**Figure 2.** Relative mRNA expression ratio of (A) nerve growth factor (NGF), (B) M<sub>2</sub>, and (C) M<sub>3</sub> (C) after middle cerebral artery occlusion (MCAO). The mRNA expressions of NGF and M<sub>2</sub> decrease after MCAO but increase at 7 days following preischemic CD34<sup>+</sup> cell treatment (6 rats in each group). M<sub>3</sub> mRNA expression significantly decreases after MCAO but increases at 1 day and 3 days after CD34<sup>+</sup> cell treatment. \*Compared with sham-operated group,  $p < 0.05$ . Pretreatment: preischemic treatment, posttreatment: postischemic treatment.

Anesthesia was discontinued after these procedures were complete. After a 60-minute occlusion of the left MCA, rats were reanesthetized, and the wound was opened to remove the nylon surgical thread to allow for the reperfusion of the MCA. In the sham-operated group, similar procedures were conducted without ligation or occlusion of any vessel. Endovascular suture occlusion of the MCA for 60 minutes would result in irreversible cerebral ischemic injury in both the cerebral cortex and striatum [12]. Therefore, we only included animals that exhibited right side weakness with upper limb dominance.

#### Preparation of CD34<sup>+</sup> cells for transplantation

After informed consent, HUCB was obtained from healthy individuals using a VarioMACS Starting Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) and CD34 MicroBead Kit (Miltenyi Biotec) according to the manufacturer's protocol. The CD34<sup>+</sup> cells were collected and washed with phosphate-buffered saline (PBS) and then prepared to a final concentration of  $1 \times 10^6$  cells/0.3 mL in PBS [13]. In the CD34<sup>+</sup>-treated groups,  $1 \times 10^6$  collected CD34<sup>+</sup> cells were administered 30 minutes before or 3 hours after MCAO via the tail vein under inhalation anesthesia.

#### Suprapubic tube implantation and cystometric studies

All rats received suprapubic tube implantation under isoflurane general anesthesia 5 days prior to implementation of MCAO. The animals were later placed in special metabolic cages (Med Associates, St. Albans, VT, USA) after MCAO to perform conscious cystometric studies according to methods described in our previous study [14]. Briefly, the suprapubic catheter was connected to a syringe pump and pressure transducer. All bladder pressures were referenced to air pressure at the level of the bladder. Pressure and force transducer signals were amplified, recorded on a chart recorder and digitized for data collection. The bladder was then filled with room temperature 0.9% saline at 5 mL/h through the bladder catheter while bladder pressure was recorded. Urine was collected in a beaker on a balance placed beneath each cage. Changes in the weight of the collection were recorded. Saline infusion was continued until rhythmic bladder micturition contractions became stable. After the initial stabilization period, data for five representative micturition cycles were collected to analyze all cystometric parameters. The following cystometric variables were investigated: peak voiding pressure, intercontraction interval, voided volume, and residual volume. Cystometry Analysis version 1.05 (Catamount Research and Development, St. Albans, Vermont, USA) was used for cystometric analysis.

#### Immunohistochemistry

After cystometric studies were completed, the rats were sacrificed and their bladders were harvested. The dissected bladders were fixed in an optimal cutting temperature compound, frozen in powdered dry ice, and stored at  $-80^\circ\text{C}$ . The bladders were then subjected to cryosectioning ( $10 \mu\text{m}$ ) at  $-18^\circ\text{C}$  with the sections mounted on glass microscope slides coated with saline (Muto Pure Chemical, Tokyo, Japan).


Immunostaining against NGF, M<sub>2</sub>, and M<sub>3</sub> in fresh-frozen bladder sections was performed with an avidin-biotin peroxidase method using a kit (PK-6102, Vector Laboratories, Burlingame, CA, USA). First, fresh-frozen sections were fixed in 4% paraformaldehyde for 10 minutes, air dried, and then rinsed with PBS. After blocking with Dako REAL peroxidase blocking solution (code S2023, DAKO Corporation, Carpinteria, CA, USA) for 20 minutes, sections were washed and incubated for 18–20 hours at  $4^\circ\text{C}$  with a



rabbit polyclonal antibody directed against NGF at a 1:250 dilution (Chemicon International, Temecula, CA, USA) or rabbit polyclonal antibody directed against M<sub>2</sub> and M<sub>3</sub> at a 1:2000 dilution (Chemicon International). Endogenous peroxidase was blocked for 10 minutes with 0.2% H<sub>2</sub>O<sub>2</sub> and 100% methanol. Then, sections were washed and incubated for 1 hour using biotinylated anti-rabbit immunoglobulin G antibody for NGF, M<sub>2</sub>, and M<sub>3</sub> at a 1:500 dilution (Vector Laboratories). This was followed by incubation for 1 hour with avidin-biotin-horseradish peroxidase complex at a 1:100 dilution. Staining was developed with 3,3'-diaminobenzidine plus hydrogen peroxide as the chromogen. All incubations were performed at room temperature except for the use of primary antibody. Negative control slides were prepared from the same tissue blocks by omitting the specific primary antibodies and using normal, nonimmune serum supernatant from the same sources. The ratio of the optical density of no treatment, pre-, or post-treatment MCAO rat to that of sham-operated rat was determined in NGF, M<sub>2</sub>, and M<sub>3</sub> analyses. Image-Pro Plus Software (Media Cybernetics, Silver Spring, MD, USA) was used for immunohistochemical measurement calculations.

#### Real-time PCR

Real time PCR was carried out according to the manufacturer's protocol. Total RNAs were prepared using a Trizol reagent (Invitrogen, Carlsbad, CA, USA) and incubated in reverse transcription mixture at 25°C for 5 minutes, 50°C for 1 hour, and 70°C for 15 minutes; finally, the tubes were cooled to 4°C for 5 minutes. Gene expression for NGF, M<sub>2</sub>, and M<sub>3</sub> in the bladder tissue was analyzed by real time PCR using inventoried TaqMan assays from Applied Biosystems (Life Technologies, Grand Island, NY, USA). The NGF, M<sub>2</sub>, and M<sub>3</sub> assays codes were Rn01533872-m1, Rn02532311-s1, and Rn00560986-s1, respectively (Applied Biosystems). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) assays codes (Rs99999916-s1) were used as an endogenous control to allow for quantification of relative gene expression. Thermal cycling and fluorescence detection were performed using an ABI Prism 7900HT Sequence Detection System (Applied Biosystems). PCR conditions were 50°C for 2 minutes, 95°C for 10 minutes, followed by 40 cycles at 95°C for 15 seconds and 60°C for 1 minute.



**Figure 3.** Temporal expressions of nerve growth factor (NGF) immunoreactivity in middle cerebral artery occlusion (MCAO) rat bladder (6 rats in each group). Expression of NGF immunoreactivity decreases at 3 days and 7 days after MCAO, but significantly increases following preischemic CD34<sup>+</sup> cell treatment. Bar indicates 20  $\mu$ m. \*Compared with sham-operated group,  $p < 0.05$ . Pretreatment: preischemic treatment, posttreatment: postischemic treatment.

The data were calculated using the  $2[-\Delta\Delta C(T)]$  method [15]. A ratio of the mRNA level of ischemic rats to that of sham-operated rats was determined. The values were summed and expressed as mean  $\pm$  standard deviation and were compared statistically among sham operation and each time point in each group.

#### Statistical analysis

The data were analyzed statistically using one-way analysis of variance test followed by a Tukey test. Values were considered significant at  $p < 0.05$ . Prism 5 software for statistical analysis (GraphPad, San Diego, CA, USA) was used for all data.


#### Results

Cystometric results showed ischemic rats have an increase in peak voiding pressure and residual volume at 1 day, 3 days, and 7

days following MCAO, which declined after pre- and posts ischemic CD34<sup>+</sup> cells treatment (Figure 1). Voided volumes and intercontraction intervals significantly decreased after MCAO, but increased after pre- and posts ischemic CD34<sup>+</sup> cells treatment at 3 days and 7 days.


The mRNA expressions of NGF and M<sub>2</sub> decreased after MCAO, but increased at 7 days following preischemic CD34<sup>+</sup> cell treatment (Figure 2). M<sub>3</sub> mRNA expression significantly decreased after MCAO, but increased at 1 day and 3 days after CD34<sup>+</sup> cell treatment.

Expression of NGF immunoreactivity decreased at 3 days and 7 days after MCAO, but significantly increased following preischemic CD34<sup>+</sup> cell treatment (Figure 3). Expression of M<sub>2</sub> immunoreactivity increased at 3 days and 7 days after MCAO, but declined to the levels of the sham-operated group after CD34<sup>+</sup> treatment (Figure 4). Expression of M<sub>3</sub> immunoreactivity significantly decreased at 1 day, 3 days, and 7 days after MCAO, but increased after CD34<sup>+</sup> cell treatment (Figure 5). Unlike the effect of



**Figure 4.** Temporal expressions of M<sub>2</sub> immunoreactivity in middle cerebral artery occlusion (MCAO) rat bladder (6 rats in each group). Expression of M<sub>2</sub> immunoreactivity increases at 3 days and 7 days after MCAO, but declines to the levels of the sham-operated group after CD34<sup>+</sup> treatment. Bar indicates 20  $\mu$ m. \*Compared with sham-operated group,  $p < 0.05$ . Pretreatment: preischemic treatment, posttreatment: posts ischemic treatment.





**Figure 5.** Temporal expressions of M<sub>3</sub> immunoreactivity in middle cerebral artery occlusion (MCAO) rat bladder (6 rats in each group). Expression of M<sub>3</sub> immunoreactivity significantly decreases at 1 day, 3 days, and 7 days after MCAO but increases after CD34<sup>+</sup> cell treatment. Bar indicates 20 μm. \*Compared with sham-operated group,  $p < 0.05$ . Pretreatment: preischemic treatment, posttreatment: postischemic treatment.

preischemic CD34<sup>+</sup> cell treatment, postischemic CD34<sup>+</sup> cells transplantation did not upregulate the expression of NGF, M<sub>2</sub>, and M<sub>3</sub> mRNA to the levels of the sham group at 7 days after MCAO.

## Discussion

Voiding dysfunction is a common sequela of cerebral stroke [16]. Maruyama et al [9] reported that rats with cerebral infarction show a significant decrease in bladder capacity, resulting in a shortening of the micturition interval and a decrease in voided volume. The bladder capacity of cerebral-infarcted rats is significantly reduced which may be mediated by two mechanisms: (1) upregulation of an excitatory pathway from the forebrain; and (2) downregulation of a tonic inhibitory pathway from the forebrain [3]. Vendrame et al [17] measured infarct volume in an MCAO rat stroke model and demonstrated a dose relationship between HUCB cells, behavioral improvement, and neural sparing. However, no study has reported that HUCB cells can mediate therapeutic effects on bladder

dysfunction after stroke. The cystometric data in the present study showed that rats undergoing MCAO have a significant increase in peak voiding pressure and residual volume. Conversely, voided volumes and intercontraction intervals significantly decrease after MCAO, but variables of urodynamic testing return to the levels of sham-operated rats after HUCB-derived CD34<sup>+</sup> cell treatment.

NGF is normally present in bladder muscle cells and urothelium [18]. Previous study showed that bilateral vesical artery ligation in rats may cause damage of detrusor muscle and there is decreased NGF immunofluorescence and elevated NGF mRNA in bladder [19]. Liang et al [14] found that NGF immunoreactivity and mRNA in the bladder muscle were transiently increased at 1 day, and declined significantly at 7 days and 28 days after bilateral common carotid artery occlusion in rats. The current results demonstrate that the decrease in bladder NGF immunoreactivity and mRNA expression that occurs in rats 3–7 days after MCAO can be reversed to an increase in NGF expression following preischemic CD34<sup>+</sup> cell treatment, due to an amelioration of the ischemic insult of brain. A

previous report indicates that cerebral stroke may modulate peripheral NGF levels [20]. Serum NGF levels were significantly related to stroke severity and the volume of brain infarction in the immediate poststroke period [20].

Rat bladder muscle is enriched with muscarinic receptors [21]. The mechanism underlying the regulation of muscarinic receptors in the bladder following cerebral infarction is still unclear. Some authors have suggested that cerebral infarction reduces parasympathetic tone in the bladder, thereby inducing compensatory upregulation of muscarinic receptors [9]. Results of our study show that expression of M<sub>2</sub> immunoreactivity in the bladder is increased, but M<sub>3</sub> immunoreactivity is decreased in the 7 days after MCAO. M<sub>3</sub> receptors are a minority population in this tissue, but they have been shown to play a predominant role in mediating most of the detrusor contractility under normal physiological conditions [22,23]. However, when compared with normal controls, there is a 50% increase in total receptor density and a 60% increase in M<sub>2</sub> but not M<sub>3</sub> receptor density in the denervated bladder [24]. Spinal cord injury in the rat may induce bladder hypertrophy and a change in muscarinic receptor subtype from M<sub>3</sub> toward M<sub>2</sub> [25]. Our data also reveal that the expression of M<sub>2</sub> mRNA and M<sub>3</sub> mRNA in the bladder decreases after MCAO in the untreated group. However, this expression may return to sham group levels after preischemic CD34<sup>+</sup> cell treatment.

In previous studies, systemic administration of HUCB-derived CD34<sup>+</sup> cells to MCAO rodents has been found to induce the neovascularization in the ischemic zone that is essential for neuronal regeneration and functional recovery after stroke [1]. Only a few studies regarding stem cell treatment in bladder diseases have been conducted [26–28]. Some investigators have reported that local injection of muscle-derived [28] or bone marrow stem cells may ameliorate impaired detrusor contractility in injured bladder rodent models [26,27]. However, adult stem cells from bone marrow and muscle are difficult to obtain, and they have the disadvantages of restricted differentiation potential, decreasing number with age, and a shorter life span compared with HUCB or amniotic fluid stem cells [29].

This study has some limitations. First, the present study did not demonstrate the therapeutic effect of CD34<sup>+</sup> cells on behavior recovery and on the infarct size in the ischemic brain. Further study is needed to illustrate the mechanism of neuroprotection by CD34<sup>+</sup> cells, which may promote hemodynamic and functional recovery of the brain after MCAO. Second, we did not use the menopausal rats instead of bilateral ovariectomized rats. Third, bladder injection of CD34<sup>+</sup> cells may improve bladder dysfunction induced by MCAO. Future research on this topic deserves to be conducted.

In conclusion, the present study shows that MCAO in rats results in changes of bladder NGF and muscarinic receptors and that such regulation of bladder receptors may be at least partly associated with the symptoms of bladder dysfunction induced by cerebral infarction. Our results demonstrate that bladder dysfunction in a rat model caused by MCAO may be restored to normal micturition by treatment with HUCB-derived CD34<sup>+</sup> cells and that this improvement may be related to the expression of NGF, M<sub>2</sub>, and M<sub>3</sub> in the bladder.

## Conflicts of interest

All authors declare no conflicts of interest.

## Acknowledgments

We would like to thank the Molecular Imaging Center, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan

for their assistance, the Research and Development Department, HealthBanks Biotech Co., Ltd., Taipei, Taiwan and professor Sheng-Hsien Chen for their technical support in CD34<sup>+</sup> purification. This work was supported by Chang Gung Memorial Hospital grant CMRPG3C1201 and the National Science Council of ROC grant NSC 99-2314-B-182A-043-MY3.

## References

- Taguchi A, Soma T, Tanaka H, Kanda T, Nishimura H, Yoshikawa H, et al. Administration of CD34<sup>+</sup> cells after stroke enhances neurogenesis via angiogenesis in a mouse model. *J Clin Invest* 2004;114:330–8.
- Yokoyama O, Yoshiyama M, Namiki M, de Groat WC. Glutamatergic and dopaminergic contributions to rat bladder hyperactivity after cerebral artery occlusion. *Am J Physiol* 1999;276:R935–42.
- Yokoyama O, Yoshiyama M, Namiki M, de Groat WC. Role of the forebrain in bladder overactivity following cerebral infarction in the rat. *Exp Neurol* 2000;163:469–76.
- Yokoyama O, Ootsuka N, Komatsu K, Kodama K, Yotsuyanagi S, Niikura S, et al. Forebrain muscarinic control of micturition reflex in rats. *Neuropharmacology* 2001;41:629–38.
- Yokoyama O, Yoshiyama M, Namiki M, de Groat WC. Changes in dopaminergic and glutamatergic excitatory mechanisms of micturition reflex after middle cerebral artery occlusion in conscious rats. *Exp Neurol* 2002;173:129–35.
- Kanie S, Yokoyama O, Komatsu K, Kodama K, Yotsuyanagi S, Niikura S, et al. GABAergic contribution to rat bladder hyperactivity after middle cerebral artery occlusion. *Am J Physiol* 2000;279:R1230–8.
- Lee TH, Yang JT, Ko YS, Kato H, Itoyama Y, Kogure K. Influence of ischemic preconditioning on levels of nerve growth factor, brain-derived neurotrophic factor and their high affinity receptors in hippocampus following forebrain ischemia. *Brain Res* 2008;1187:1–11.
- Ochodnicki P, Cruz CD, Yoshimura N, Michel MC. Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target. *NeuroUrol Urodyn* 2011;30:1227–41.
- Maruyama S, Kurosawa S, Takagi Y, Oki T, Noguchi Y, Ukai M, et al. Urodynamics and bladder muscarinic receptors in rats with cerebral infarction and bladder outlet obstruction. *Neurosci Lett* 2007;414:80–4.
- Alkayed NJ, Harukuni I, Kimes AS, London ED, Traystman RJ, Hurn PD. Gender-linked brain injury in experimental stroke. *Stroke* 1998;29:159–66.
- Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a meta-analysis. *Stroke* 2009;40:2438–41.
- Lee TH, Kato H, Chen ST, Kogure K, Itoyama Y. Expression of nerve growth factor and trkA after transient focal cerebral ischemia in rats. *Stroke* 1998;29:1687–96.
- Chen SH, Chang FM, Chang HK, Chen WC, Huang KF, Lin MT. Human umbilical cord blood-derived CD34<sup>+</sup> cells cause attenuation of multiorgan dysfunction during experimental heatstroke. *Shock* 2007;27:663–71.
- Liang CC, Lin YH, Liu HL, Lee TH. Bladder dysfunction induced by cerebral hypoperfusion after bilateral common carotid artery occlusion in rats. *NeuroUrol Urodyn* 2015;34:586–91.
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>-</sup>(Delta Delta C(T)) Method. *Methods* 2001;5:402–8.
- Sakakibara R, Hattori T, Yasuda K, Yamanishi T. Micturitional disturbance after acute hemisphere stroke: analysis of the lesion site by CT and MRI. *J Neurol Sci* 1996;137:47–56.
- Vendrame M, Cassady J, Newcomb J, Butler T, Pennypacker KR, Zigova T, et al. Infusion of human umbilical cord blood cells in a rat model of stroke dose-dependently rescues behavioral deficits and reduces infarct volume. *Stroke* 2004;35:2390–5.
- Steers WD, Tuttle JB. Mechanisms of disease: the role of nerve growth factor in the pathophysiology of bladder disorders. *Nat Clin Pract Urol* 2006;3:101–10.
- Liang CC, Lee TH, Tseng LH. Expression of nerve growth factor immunoreactivity and messenger RNA in ischemic urinary bladder. *NeuroUrol Urodyn* 2010;29:512–6.
- Stanzani L, Zoia C, Sala G, Appollonio I, Frattola L, De Simoni MG, et al. Nerve growth factor and transforming growth factor-beta serum levels in acute stroke patients. Possible involvement of neurotrophins in cerebrovascular disease. *Cerebrovasc Dis* 2001;12:240–4.
- Monferini E, Giraldo E, Ladinsky H. Characterization of the muscarinic receptor subtypes in the rat urinary bladder. *J Pharmacol* 1988;147:453–8.
- Wang P, Luthin GR, Ruggieri MR. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. *J Pharmacol Exp Ther* 1995;273:959–66.
- Longhurst PA, Leggett RE, Briscoe JA. Characterization of functional muscarinic receptors in the rat urinary bladder. *Br J Pharmacol* 1995;116:2279–85.
- Braverman AS, Luthin GR, Ruggieri MR. M2 muscarinic receptor contributes to contraction of the denervated rat urinary bladder. *Am J Physiol Regul Integr Comp Physiol* 1998;275:R1654–60.

- [25] Braverman AS, Ruggieri Sr MR. Hypertrophy changes the muscarinic receptor subtype mediating bladder contraction from M3 toward M2. *Am J Physiol Regul Integr Comp Physiol* 2003;285:R701–8.
- [26] Nishijima S, Sugaya K, Miyazato M, Kadekawa K, Oshiro Y, Uchida A, et al. Restoration of bladder contraction by bone marrow transplantation in rats with underactive bladder. *Biomed Res* 2007;28:275–80.
- [27] De Coppi Paolo, Callegari A, Chiavegato A, Gasparotto L, Piccoli M, Taiani J, et al. Amniotic fluid and bone marrow derived mesenchymal stem cells can be converted to smooth muscle cells in the cryo-injured rat bladder and prevent compensatory hypertrophy of surviving smooth muscle cells. *J Urol* 2007;177:369–76.
- [28] Lee JY, Piao S, Kim IG, Byun SS, Hwang JH, Hong SH, et al. Effect of human muscle-derived stem cells on cryoinjured mouse bladder contractility. *Urology* 2012;80:224.e7–e11.
- [29] Tsai MS, Lee JL, Change YJ, Hwang SM. Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. *Hum Reprod* 2004;19:1450–6.